Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics

歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT SELECTION OF THE SHARES OF THE COMPANY AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED

This announcement is made by Ocumension Therapuetics (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The board of directors of the Company (the "Board") is pleased to announce that the Company has been selected as a constituent stock of the following index series by the Hang Seng Indexes Company Limited, with effect from March 15, 2021:

- 1. Hang Seng Composite Index; and
- 2. Hang Seng Healthcare Index.

By being selected as a constituent stock of the above Hang Seng Indexes, we have satisfied one of the criteria for being eligible as the Southbound Trading stocks under the Stock Connect scheme, which is a channel that facilitates stock trading and investment between Hong Kong and a broader base of China investors.

The Board would like to thank the shareholders of the Company and investors for their continued support of the Company. The Company endeavors to make use of its competitive advantages to expand its business and to create value for its stakeholders.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, March 1, 2021

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.